Analyst Joseph Stringer from Needham maintained a Buy rating on Stoke Therapeutics and keeping the price target at $35.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Joseph Stringer has given his Buy rating due to a combination of factors related to Stoke Therapeutics’ ongoing developments. The company’s pivotal Phase 3 trial for zorevunersen in Dravet Syndrome is progressing ahead of schedule, with a significant number of patients already randomized and more identified as potential candidates. This progress suggests a strong potential for successful trial outcomes.
Moreover, Stoke Therapeutics is actively engaging with the FDA to explore expedited approval pathways, which could accelerate the drug’s market entry and enhance the company’s growth prospects. The possibility of an expedited approval presents an upside potential for the stock, reinforcing the Buy rating. Overall, the combination of trial progress and regulatory engagement underpins a positive outlook for Stoke Therapeutics.
According to TipRanks, Stringer is a 5-star analyst with an average return of 18.8% and a 46.09% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Gilead Sciences, and Stoke Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $35.00 price target.